VoxCell BioInnovation specializes in advanced bioprinting technologies that enhance drug discovery and preclinical testing by creating human-like tissue models. Their platform utilizes bioink formulations designed to replicate the extracellular matrix of living tissues, enabling the development of 3D hydrogels that mimic the chemical and mechanical properties of various soft tissue types. This innovative approach allows for the generation of customizable vascular structures and cell line compositions, providing predictive results for drug distribution and efficacy. By integrating these models into the drug screening process, VoxCell aims to deliver translatable data that overcomes the limitations of traditional methodologies.

One of the key products offered by VoxCell is the Universal Bioink™ Kit, a versatile polymeric mixture engineered for compatibility with various bioprinting technologies, including extrusion-based and digital light processing (DLP) systems. This kit is designed to facilitate the creation of tissue models that can be tailored to specific research needs, with the ability to support multiple cell lines and media types. The Universal Bioink™ is delivered in a sterile format, ensuring ease of use and safety in laboratory settings. By providing these advanced tools, VoxCell BioInnovation is positioned to significantly accelerate the preclinical pathway for drug development, ultimately contributing to more effective therapeutic solutions.

Canada

Not another bioprinting company. 

VoxCell BioInnovation is redefining tissue engineering for the drug development industry. We specialize in creating an extraordinary line of vascularized human-like cancer tissue models, enabling pharmaceutical companies to identify unviable drug candidates earlier in the development process. 

Operating as a screening platform without FDA approval, we accelerate therapy development, ensuring life-saving treatments reach those in need faster.

VoxCell BioInnovation

Company Details